Description
Presenter:Stephanie Knatz Peck PHD
Overview.
Psychiatric illnesses affect a large proportion of the population and can be costly and difficult to treat successfully. Despite their seriousness to society, there have been minimal advancements in novel behavioral treatment strategies and stagnant outcomes over the past several decades. Novel and innovative treatments methods are urgently needed to improve treatment engagement and outcomes (Grinstein, 2024). One such avenue may be psychedelic treatment, which includes the supported delivery of psychedelic medicine delivered in conjunction with therapy. There has been a surgency of interest and study of psychedelic treatments, including rigorous, randomized controlled trials for major depressive disorder and substance use disorders, and smaller studies underway for a number of other mental health indications (Vollenweider & Preller, 2020; Sicignano, Hernandez, Schiff, Elmahy,& White, 2024). Results from these studies indicate significant promise, in some cases for otherwise treatment resistant populations and pathways for approval of these treatments are currently being pursued to facilitate therapeutic access legally to those who may benefit (Van Amsterdam & van den Brink, 2022). Psychologists will need to be prepared for the advent of these novel treatment models. This presentation will provide an overview of the current state of the literature with a particular focus on the state of the evidence for psychedelic treatments and mental health indications for which there may be promise based on available studies, and current knowledge related to mechanisms of action (van Elk & Yaden, 2022).
Objectives.
- Describe the basic framework being studied for providing psychological support alongside psychedelic medicines
- Explain the current state of the research for psychedelic treatments in clinical settings.
- List mental illnesses for which psychedelic treatments may be indicated based on extant research,
About the Presenter.
Dr. Stephanie Knatz Peck (Ph.D) is a clinical psychologist and Voluntary Associate Clinical Professor at the University of California, San Diego Department of Psychiatry.. She served as co-investigator on two trials evaluating psilocybin for anorexia nervosa and served as lead psychologist on trials evaluating psilocybin for treatment resistant depression and anorexia nervosa. She has experience delivering both psilocybin therapy and ketamine-assisted therapy for mental health populations, and is also trained in psychological support models for other psychedelic drugs. She has served as a senior clinical consultant, subject matter expert and lead content developer for Compass Pathways assisting with the development of content related to their psychological support model and therapist training program for indications including treatment resistant depression and anorexia nervosa. She currently provides ongoing training for Compass clinical trial therapists. Stephanie is passionate about developing and disseminating psychedelic therapy models in mainstream clinical settings that support safe and healing psychedelic experiences for mental health populations.
Cost
FREE for MEMBERS
$40.00 for Non-Members